Company Statements
05/09/2023
Gilead Statement on Favorable Verdict in HIV PrEP Patents Litigation
04/03/2023
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts
03/30/2023
Gilead Sciences Statement on Sustaining Access to AmBisome® in Low- and Middle-Income Countries
02/17/2023
Christi Shaw to Depart Gilead and Kite Leadership End of Q1
02/09/2023
12/23/2022
10/27/2022
09/28/2022
08/16/2022
08/03/2022
07/27/2022
Gilead Sciences Statement on FDA Acceptance of New Drug Application for Investigational Lenacapavir
06/24/2022
Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade
06/03/2022
All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S.
04/21/2022
03/15/2022
Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products
03/09/2022
Gilead to Expand Footprint in Oceanside
02/08/2022
Gilead Expands Availability of Veklury® (remdesivir) to Non-Hospital Outpatient Facilities
02/01/2022
Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare
01/19/2022
Gilead Announces Actions to Remove Counterfeit HIV Medications from U.S. Supply Chain
01/14/2022
Gilead Statement on Zydelig® U.S. Indication for Follicular Lymphoma and Small Lymphocytic Leukemia
12/17/2021
12/3/2021
12/01/2021
Gilead Statement on Veklury® (Remdesivir) and the SARS-CoV-2 Omicron Variant
11/23/2021
10/20/2021
09/27/2021
08/09/2021
Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees
08/05/2021
Gilead Warns of Counterfeit HIV Medication Being Distributed in the United States
07/21/2021
07/02/2021
Gilead Sciences Response to Open Letter Regarding Access to AmBisome® (liposomal amphotericin B)
04/21/2021
04/12/2021
04/09/2021
04/08/2021
Gilead Announces Updates to The Advancing ACCESS® Patient Assistance/Medication Assistance Program
02/09/2021
02/07/2021
Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD
01/13/2021
Gilead Sciences Statement on Recent Events in Washington, D.C.
12/21/2020
11/19/2020
10/15/2020
Gilead Sciences Statement on the Solidarity Trial
09/23/2020
Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations
09/23/2020
07/08/2020
06/17/2020
06/01/2020
Gilead Sciences Statement on Remdesivir Clinical Data
05/29/2020
Gilead Sciences Response to U.S. Senators on Trial Diversity
05/22/2020
Gilead Sciences Statement on NEJM Publication of Remdesivir Data From NIAID Study
08/06/2020
Gilead Sciences Update on Veklury® (Remdesivir) Manufacturing Network
05/05/2020
Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir
08/05/2020
Gilead Sciences Statement on State Attorneys General Letter on Remdesivir
04/24/2020
Gilead Statement on Complaint Against Federal Government in The Court of Federal Claims
04/23/2020
Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China
04/10/2020
Gilead Sciences Response to Médecins Sans Frontières
03/25/2020
Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation
03/23/2020
Gilead Sciences Statement on Ensuring Continued Supply of HIV Medicine Amid Coronavirus Outbreak
03/22/2020
Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials
02/05/2020
01/31/2020
12/03/2019
11/07/2019
Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents
08/21/2019
Petitions to US Patent and Trademark Office on HIV PrEP Patents
06/11/2019
05/14/2019
Gilead Sciences Statement On Inaccurate Reporting On Truvada®
04/10/2019
Gilead Sciences Statement on Commitment to Providing Price Information
04/04/2019
Gilead Sciences Commits to Reducing our Global Greenhouse Gas Emissions by 25 Percent by 2025
04/03/2019
09/27/2018
09/24/2018
A perspective from our CEO: Gilead Subsidiary to Launch Authorized Generics to Treat HCV
09/07/2018
05/02/2018
Gilead Publishes 2017 Year in Review
11/09/2017
Gilead Sciences Announces 100 Percent Score on 2018 Human Rights Campaign Corporate Equality Index
09/01/2017
Gilead Implements Emergency Disaster Response Procedures to Ensure Medicine Access
05/01/2017
Gilead Publishes Year in Review 2016
12/06/2016
Gilead Recognized as Top Corporate Philanthropist in Funders Concerned About AIDS Report
12/01/2016
Gilead HIV Medicines Now Reaching 10 Million People in Developing Countries
11/11/2016
Statement on DISCOVER Study of F/TAF for PrEP
08/01/2016
Gilead Publishes 2015 Corporate Social Responsibility Report
08/14/2015
Gilead Supports PrEP Education to Increase HIV Prevention and Awareness
08/12/2015
Some of the content on this page is not intended for users outside